Emergence of SARS-CoV-2 Omicron (B. 1.1. 529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic
Since the appearance in the late of December 2019, SARS-CoV-2 is rapidly evolving and
mutating continuously, giving rise to various variants with variable degrees of infectivity and …
mutating continuously, giving rise to various variants with variable degrees of infectivity and …
[HTML][HTML] Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Despite the need for novel, effective therapeutics for the COVID-19 pandemic, no curative
regimen is yet available, therefore patients are forced to rely on supportive and nonspecific …
regimen is yet available, therefore patients are forced to rely on supportive and nonspecific …
Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients
R Najjar-Debbiny, N Gronich, G Weber… - Clinical Infectious …, 2023 - academic.oup.com
Background Paxlovid was granted an Emergency Use Authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …
[HTML][HTML] Omicron (B. 1.1. 529) variant of SARS‐CoV‐2: concerns, challenges, and recent updates
Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …
The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce …
RP Joyce, VW Hu, J Wang - Medicinal Chemistry Research, 2022 - Springer
The rapid development of effective vaccines to combat the SARS-CoV-2 virus has been an
effective counter measure to decrease hospitalization and the mortality rate in many …
effective counter measure to decrease hospitalization and the mortality rate in many …
Oral antiviral treatments for COVID-19: opportunities and challenges
L Rahmah, SO Abarikwu, AG Arero, M Essouma… - Pharmacological …, 2022 - Springer
The use of antiviral COVID-19 medications can successfully inhibit SARS-CoV-2 replication
and prevent disease progression to a more severe form. However, the timing of antiviral …
and prevent disease progression to a more severe form. However, the timing of antiviral …
Targeting SARS-CoV-2 papain-like protease in the postvaccine era
While vaccines remain at the forefront of global healthcare responses, pioneering
therapeutics against SARS-CoV-2 are expected to fill the gaps for waning immunity. Rapid …
therapeutics against SARS-CoV-2 are expected to fill the gaps for waning immunity. Rapid …
Molnupiravir, nirmatrelvir/ritonavir, or sotrovimab for high-risk COVID-19 patients infected by the omicron variant: hospitalization, mortality, and time until negative …
L Cegolon, R Pol, O Simonetti, F Larese Filon… - Pharmaceuticals, 2023 - mdpi.com
Background. Several drugs which are easy to administer in outpatient settings have been
authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to …
authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to …
Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19
Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has brought an unprecedented public health crisis …
syndrome coronavirus 2 (SARS-CoV-2), has brought an unprecedented public health crisis …
Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
F Baldi, C Dentone, M Mikulska, D Fenoglio… - Frontiers in …, 2023 - frontiersin.org
COVID-19 in immunocompromised patients is difficult to treat. SARS-CoV-2 interaction with
the host immune system and the role of therapy still remains only partly understood. There …
the host immune system and the role of therapy still remains only partly understood. There …